EN
menu
Schott Pharma Logo

How can we continue to drive megatrends in the pharmaceutical industry as a pure-player in injectables? How can we solve the challenges of our customers with our innovations? How can we, as a market leader, increase our profitability and continue to inspire investors? How can we achieve a sustainable transformation? And what are we doing to further strengthen and expand our global competitive position? Join the dialogue, find out where we are headed and discover new perspectives.

 

 

What’s next after SCHOTT Pharma’s successful IPO?

“Our successful start on the stock market affirmed our market position and also reinforced our aspiration for the future. For this, we are focusing our strategy on innovation, expansion and being a trusted partner to the industry. Our profitable track record and an increase in the revenue share of High-Value Solutions to 48% in the past financial year clearly show that we are on the right path.”

Andreas Reisse, CEO, SCHOTT Pharma

CFO_Almuth_Steinkuehler.png

Was 2023 a good year for SCHOTT Pharma?

“2023 was indeed a successful year: we delivered on our promises, met all our targets and guidance and achieved profitable growth. Following a good start into 2024, we are confident that we will be able to maintain our strong business momentum and continue to benefit from key trends in the pharmaceutical industry and from general market growth for injectable drugs.”

Dr. Almuth Steinkühler, CFO SCHOTT Pharma

m €
Record level of revenues
%
Stable EBITDA margin
%
Revenue share of HVS products
m €
Forward-looking investments for capacity expansion

What do 100 years of experience mean for the future?

“As part of the SCHOTT Group, SCHOTT Pharma has been proving its innovative strength and market experience, time and again, for more than 100 years. Our aim is to continue to improve healthcare around the world, together with strong partners. It is this ambition and our corporate success story that provide the foundation for our vision for the future: We want to further expand our position as one of the leading manufacturers of drug containment and delivery systems for injectable drugs and biologics, to play a key part in improving sustainability within the industry and to provide product quality at the highest levels.”

Dr. Bertram Kimmerle, Head of R&D and Global Engineering SCHOTT Pharma

Bertram_Kimmerle.png
Yen_Schiffner.png

How will SCHOTT Pharma benefit from new market trends?

“We are constantly expanding our strong market position thanks to a variety of emerging trends offering enormous potential for growth and revenue generation, such as mRNA, GLP-1 drugs, and biologics. Our High-Value Solutions and innovations such as our sterilised products ensure that we are not only responding to these trends but are actively driving demand. Every minute of every day, more than 25,000 injections are provided to patients worldwide through one of our products. And yet, thepotential is far from exhausted.”

Yen Schiffner, Head of Market Intelligence & Training SCHOTT Pharma

What are the strengths of SCHOTT Pharma’s product portfolio?

“Time and again, we have succeeded in bringing imrpoved and more innovative solutions to the market to safely store drugs. Our SCHOTT TOPPAC® freeze prefillable polymer syringe is one recent example: It is particularly suitable for drugs that need to be stored and transported at temperatures approaching -100°C. To date, syringes have not been a practical solution for such deep-cold medicines. SCHOTT TOPPAC® freeze now makes it possible to bring mRNA-based drugs – used for treating respiratory infections, for example – to market in prefillable polymer syringes.”

Tom Van Ginneken, Head of Global Product Management Polymer Solutions SCHOTT Pharma

Tom_Van_Ginneken.png
Diana_Loeber.png

What makes SCHOTT Pharma’s products so successful?

“Our customers are working on bringing life-saving drugs to market – fast. And our solutions are designed to help them do so with maximum efficiency. A prime example of this is SCHOTT Pharma’s sterile ready-to-use solutions, which drug manufacturer can use to fill drugs faster and more flexibly. This enhances product quality and patient safety, while significantly shortening time to market.”

Diana Loeber, Global Product Manager Bulk & Sterile Solutions SCHOTT Pharma

What does SCHOTT Pharma’s sustainability strategy mean for the Company’s future direction?

“Sustainability is a crucial part of our strategy. Our products make a significant contribution to global healthcare, as they allow to safely store and administer around 13 billion injections of vital drugs every year. Together with our customers and partners, our ambition is to develop solutions and manufacturing processes that meet both patient safety and environmental requirements.”

Dr. Arne Kloke, Head of Sustainability SCHOTT Pharma

Portrait_Arne_Kloke_3.png

Document Downloads

Annual Report 2022/2023 (PDF) Sustainability Report 2022/2023 Press information Financial Statement of SCHOTT Pharma AG & Co. KGaA (HGB) 2022/2023